Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07581951 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Enrollment increased: 400 → 886 participants · Study sites: 0 to 1 · Eligibility criteria expanded, about 14 words · 1 more Show 4 more changesShow less
    • Enrollment increased: 400 → 886 participants
    • Study sites: 0 to 1
    • Eligibility criteria expanded, about 14 words
    • Study description expanded, about 73 words
  2. Primary endpoint(s) modified Completion pushed from Aug 30, 2029 to Dec 30, 2032 · Eligibility criteria shortened, about 21 wordsv2 Show 2 more changesShow less
    • Completion pushed from Aug 30, 2029 to Dec 30, 2032
    • Eligibility criteria shortened, about 21 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of HSK31679 compared to placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH) .
Trial Details
NCT Number NCT07581951
Lead Sponsor Haisco Pharmaceutical Group Co., Ltd.
Conditions MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH (Non-Alcoholic Steatohepatitis)
Enrollment 886 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov